The Food and Drug Administration confirmed that Esperion Therapeutics Inc.'s (Nasdaq: ESPR) LDL-C lowering program was adequate to support approval of an LDL-C lowering indication for bempedoic acid. The stock price leaped $17.55 to close at $41.22.
Esperion Therapeutics moves forward with LDL-C lowering program
March 20, 2017 at 17:05 PM EDT
